Since both types of molecular alterations studied in this retrospective analysis are rare, occurring in about 3–5% (BRAF V 6000E mutation) and 2–4% of NSCLC (MET exon 14 skipping mutation), robust and large-scale data on the characteristic and treatment of patients are missing, as are phase III randomized controlled trials [38,39]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.